GYRE Stock Analysis: Buy, Sell, or Hold?
GYRE - Gyre Therapeutics, Inc. Common Stock
$7.34
0.82 (12.58%)
▲
5d:
+17.82%
30d:
+32.01%
90d:
+1.52%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When GYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: GYRE is 13.4% above its trading range ($6.47). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: GYRE is 13.4% above its trading range ($6.47). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: GYRE is currently trading at $7.34, which is considered extended relative to its 30-day fair value range of $5.77 to $6.47. From a valuation perspective, the stock is trading at a discount (Forward PE: -63.8) compared to its historical average (45.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GYRE is in a strong downtrend. The price is approaching resistance at $6.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.6% recently.
Market Sentiment: GYRE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.67 (+154.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GYRE is in a strong downtrend. The price is approaching resistance at $6.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.6% recently.
Market Sentiment: GYRE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.67 (+154.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.77 -
$6.47
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price significantly overextended (+13.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.6%)
- BULLISH: Trading 154.3% below Wall St target ($18.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to 13.4% overvaluation
Trading Range Analysis
30-Day Trading Range
$5.77 -
$6.47
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.07
Resistance Level
$6.98
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-63.83
Wall Street Target
$18.67
(+154.3%)
Revenue Growth (YoY)
2.1%
Earnings Growth (YoY)
166.2%
Profit Margin
-5.4%
PE vs Historical
-63.8 vs 45.4
CHEAP
Share & Embed Analysis
Last updated: July 02, 2026 10:44 PM ET
Data refreshes hourly during market hours. Next update: 11:44 PM
Data refreshes hourly during market hours. Next update: 11:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
